How to Get Prior Authorization for Ozempic: A Step-by-Step Guide

Prior authorization (PA) for GLP-1 medications like Ozempic and Wegovy has become one of the most frustrating bottlenecks in weight management and diabetes care. Insurers require it as a cost-control mechanism, but for patients, it often feels like an obstacle course designed to make them give up. This guide walks through the process step by step — from what PA actually is to what to do when it is denied.

What Is Prior Authorization and Why Do Insurers Require It?

Prior authorization is a requirement from your health insurer that your prescribing provider obtain approval before the insurer will cover a specific medication or procedure. It is not a permanent decision — PA approvals are typically issued for a set period (often 12 months) and must be renewed.

For GLP-1 receptor agonists, PA requirements are near-universal among commercial health plans. The reason is cost: brand-name semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) carry list prices between $800 and $1,400 per month. Insurers want to confirm the medication is medically appropriate before committing to that recurring expense.

PA requirements vary by plan and by the specific drug:

• Ozempic (semaglutide for T2D): Typically requires a type 2 diabetes diagnosis, documented HbA1c above a threshold (often ≥7.0%–8.0%), and failure or contraindication to first-line agents like metformin.
• Wegovy (semaglutide for chronic weight management): Requires a BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, cardiovascular disease). Many plans also require documentation of prior behavioral intervention and sometimes a prior weight-loss medication trial.
• Mounjaro / Zepbound (tirzepatide): Similar requirements to Ozempic/Wegovy depending on the indication being submitted.

Step 1: Confirm Your Coverage and PA Requirements

Before your provider submits anything, verify what your specific plan requires:

1. Call the member services number on the back of your insurance card and ask: "Does my plan require prior authorization for Ozempic (or Wegovy)? What is your formulary tier for this medication?"
2. Ask for the specific criteria your plan uses to approve or deny the request. Insurers are legally required to disclose their clinical coverage criteria.
3. Find out which diagnosis codes and supporting documentation the plan needs.
4. Ask about the step therapy requirements — many plans require you to try and fail at least one other medication before they will approve a GLP-1.

This call takes 15–20 minutes but can prevent weeks of back-and-forth between your provider's office and the insurer.

Step 2: Talk to Your Provider

Once you understand your plan's requirements, share that information with your prescribing provider. The PA is submitted by the provider, not the patient — but you can do a lot to prepare them.

Bring to your appointment (or secure message to a telehealth provider):

• Your most recent HbA1c results (for diabetes indication) or current BMI documentation
• A list of other medications you have tried for diabetes or weight management, with approximate dates
• Any labs or records documenting weight-related comorbidities (blood pressure readings, lipid panel results, sleep study reports)
• The specific criteria your insurer shared with you

Providers who prescribe GLP-1s regularly will have PA templates on file. But the more complete your documentation, the faster the submission.

Step 3: Understand the Diagnosis Codes

The ICD-10 codes submitted on the PA request need to match the drug's approved indication. The most commonly used codes are:

Your provider selects the appropriate codes. If your claim is denied partly because of a coding mismatch, the PA can often be resubmitted with corrected codes without waiting through a full appeal.

Step 4: The Submission Process

Once your provider's office has the required documentation, they submit the PA to your insurer. This can be done electronically through the insurer's provider portal, by fax, or via phone (phone is slowest and hardest to track). Most provider offices use electronic submission.

Standard PA timelines:

• Non-urgent commercial plans: 3–7 business days (some plans commit to 72 hours)
• Urgent PA requests: 72 hours for commercial plans; 24–72 hours for Medicare Advantage
• Medicare Part D: Up to 72 hours for standard; 24 hours for expedited

Follow up with your provider's office after 5 business days if you have not received a decision. Ask them to confirm the PA was submitted and to check its status in the insurer portal.

Step 5: If You Are Approved

The insurer will send an approval letter (and typically notify your provider's office directly). The approval will specify:

• The drug approved (by NDC number)
• The quantity limit (typically a 30-day supply)
• The approval period (often 12 months)
• Any conditions on the approval (e.g., dosing schedule requirements)

Save this approval letter. You will need it when you fill your prescription and again when you reauthorize in 12 months.

Note that approval does not mean $0 cost. Your cost share (copay or coinsurance) still applies, and what you pay depends on your plan's formulary tier for the drug. Ask your pharmacist what your out-of-pocket cost will be before you pick up the prescription.

Step 6: If You Are Denied

A denial is not the end of the road. Denials happen frequently — and a large percentage are overturned on appeal.

Request a Peer-to-Peer Review First

Ask your provider's office to request a peer-to-peer (P2P) review. This is a direct call between your prescribing physician and the insurer's medical director reviewing your case. P2P reviews overturn denials in roughly 40–60% of cases, according to provider-side advocacy data. The key is that your provider can present context that does not fit neatly into checkboxes: why they believe this medication is medically necessary for you specifically.

File a Formal Internal Appeal

If the P2P does not resolve it, file a formal internal appeal. You have the right to do this under both commercial insurance and ACA marketplace plan rules.

A strong appeal package includes:

• The denial letter with the specific reason for denial
• A letter of medical necessity from your provider, addressing each denial reason directly
• Relevant clinical records: labs, visit notes, prior treatment history
• Supporting clinical literature if appropriate (your provider may attach relevant studies)

Most insurers must decide internal appeals within 30 days for pre-service requests (before you receive the medication) or 60 days for post-service requests.

Request an External Independent Review

If your internal appeal is denied, you have the right to request an external independent review by a third-party organization. This is required under federal law for most commercial plans. External reviewers overturn insurance decisions in roughly 40–45% of cases.

Consider Alternative Coverage Paths

For patients whose PA denials are upheld, there are practical alternatives to waiting through the full appeals chain:

• Manufacturer savings programs: Novo Nordisk's Ozempic Savings Offer and Wegovy Savings Card can reduce out-of-pocket costs for eligible commercially insured patients.
• Telehealth with compounded semaglutide: For patients without insurance coverage or facing repeated denials, licensed telehealth GLP-1 providers often offer compounded semaglutide or tirzepatide at a fraction of the brand-name cost. This path bypasses the insurer PA requirement entirely.
• Employer benefit negotiation: If your employer self-funds your health plan, they have direct control over formulary decisions. Some patients have successfully advocated through HR to add GLP-1 coverage.

For a complete overview of what is and is not typically covered by insurance for GLP-1 medications, see our guide to semaglutide insurance coverage.

How Telehealth Providers Help with Prior Authorization

Many telehealth platforms that prescribe GLP-1 medications have developed efficient PA workflows:

• They submit PA requests electronically, often same-day or next-day after your consultation
• They have in-house PA coordinators who know each major insurer's criteria in detail
• They can initiate P2P review calls faster than a busy primary care or endocrinology practice
• They maintain structured clinical documentation (labs, visit notes, prior treatment records) in a format designed to satisfy PA criteria from the first submission

If you have been struggling with a PA process through a traditional provider, a telehealth GLP-1 specialist may be able to navigate it more efficiently. Many patients find the secure-message communication model also makes it easier to provide follow-up documentation quickly.

Timeline Summary

This article provides general educational information about the prior authorization process and does not constitute legal or medical advice. Coverage criteria, timelines, and appeal rights vary by insurer and plan type. Consult your specific plan documents and, if needed, a patient advocate or healthcare attorney for guidance specific to your situation.